Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Hannani D, et al. Among authors: eggermont a. Cell Res. 2015 Feb;25(2):208-24. doi: 10.1038/cr.2015.3. Epub 2015 Jan 13. Cell Res. 2015. PMID: 25582080 Free PMC article.
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L. Jacquelot N, et al. Among authors: eggermont am. Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3. Cell Res. 2019. PMID: 31481761 Free PMC article.
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Hannani D, et al. Among authors: eggermont a. Cell Res. 2015 Mar;25(3):399-400. doi: 10.1038/cr.2015.28. Cell Res. 2015. PMID: 25732764 Free PMC article. No abstract available.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Vétizou M, et al. Among authors: eggermont a. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. Science. 2015. PMID: 26541610 Free PMC article.
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L. Rusakiewicz S, et al. Among authors: eggermont a. Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16. Cancer Res. 2013. PMID: 23592754
Potent immunomodulatory effects of the trifunctional antibody catumaxomab.
Goéré D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L. Goéré D, et al. Among authors: eggermont a. Cancer Res. 2013 Aug 1;73(15):4663-73. doi: 10.1158/0008-5472.CAN-12-4460. Epub 2013 Jun 4. Cancer Res. 2013. PMID: 23737485
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L. Romero AI, et al. Among authors: eggermont a. Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6. Cancer Res. 2014. PMID: 24197135 Clinical Trial.
815 results